EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access

Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model

Anna P Durbin, Liesbeth Van Wesenbeeck, Kristen K Pierce, Guillermo Herrera-Taracena, Laura Ebone, Annemie Buelens, Patricia Lutton, Beulah P Sabundayo, Veerle Van Eygen, Kim De Clerck, Isabel Fetter, Natalia V Voge und 15 weitere

New England Journal of Medicine · 27.11.2025 · 393 (21) · 2107-2118

DOI: 10.1056/nejmoa2500179 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift New England Journal of Medicine, erschienen am 27.11.2025. Verfasst von Anna P Durbin und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore. Hauptthemen laut MEDLINE: Antiviral Agents, Dengue, Dengue Virus, Drugs, Investigational. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, Division of Intramural Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDengueDengue VirusDrugs, InvestigationalAdultFemaleHumansMaleMiddle AgedYoung AdultAdministration, OralAntibodies, ViralDose-Response Relationship, DrugDouble-Blind MethodDrug Administration ScheduleRNA, ViralViral LoadTreatment Outcome

Substanzen

Antibodies, ViralAntiviral AgentsRNA, ViralDrugs, Investigational

Autor:innen und Institutionen

  • Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore.
  • Johnson & Johnson, Beerse, Belgium.
  • University of Vermont College of Medicine, Burlington.
  • Johnson & Johnson, Horsham, PA.
  • Johnson & Johnson, Spring House, PA.
  • Johnson & Johnson, San Diego, CA.

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • Division of Intramural Research

Zitieren

APA

Durbin, A. P., Van Wesenbeeck, L., Pierce, K. K., Herrera-Taracena, G., Ebone, L., Buelens, A., Lutton, P., Sabundayo, B. P., Van Eygen, V., De Clerck, K., Fetter, I., Voge, N. V., Fang, X., Goeyvaerts, N., Vandendijck, Y., Mayfield, J., Lenz, O., De Meyer, S., Kakuda, T. N., …, & Rasschaert, F. (2025). Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model. New England Journal of Medicine, 393(21), 2107-2118. https://doi.org/10.1056/nejmoa2500179

Vancouver

Durbin AP, Van Wesenbeeck L, Pierce KK, Herrera-Taracena G, Ebone L, Buelens A, et al. Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model. New England Journal of Medicine. 2025;393(21):2107-2118. doi:10.1056/nejmoa2500179

BibTeX
@article{Durbin2025,
  author = {Durbin, Anna P and Van Wesenbeeck, Liesbeth and Pierce, Kristen K and Herrera-Taracena, Guillermo and Ebone, Laura and Buelens, Annemie and Lutton, Patricia and Sabundayo, Beulah P and Van Eygen, Veerle and De Clerck, Kim and Fetter, Isabel and Voge, Natalia V and Fang, Xi and Goeyvaerts, Nele and Vandendijck, Yannick and Mayfield, Jeffrey and Lenz, Oliver and De Meyer, Sandra and Kakuda, Thomas N and He, Huili and Amaro-Carambot, Emérito and Draghia-Akli, Ruxandra and Carmolli, Marya and De Marez, Tine and Whitehead, Stephen S and Van Loock, Marnix and Rasschaert, Freya},
  title = {Daily Mosnodenvir as Dengue Prophylaxis in a Controlled Human Infection Model},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {21},
  pages = {2107--2118},
  doi = {10.1056/nejmoa2500179}
}
Kostenlos starten →